Table 1. Baseline Characteristics and univariate and multivariate logistic regression analysis of 100 consecutive patients with newly diagnosed, previously untreated AML who received venetoclax + azacitidine.
Patient characteristics are detailed in Supplementary Table S1.
NA = Not Available; NE = Not Estimable.
| Baseline Variables | Value | Univariate Analysis as a Predictor for Refractory Disease | Multivariate Analysis as a Predictor for Refractory Disease | ||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | p-value | OR | 95% CI | p-value | ||
| Age (median) | 71.5 (22-89) | 0.984 | 0.947, 1.022 | 0.4028 | |||
| Sex (female) | 51 (51%) | 3.401 | 1.002, 11.539 | 0.0495 | 2.096 | 0.417, 10.544 | 0.3694 |
| Antecedent hematologic disorder | 20 (20%) | 0.573 | 0.118, 2.772 | 0.4884 | |||
| Complex cytogenetics | 28 (28%) | 2.667 | 0.863, 8.237 | 0.0883 | |||
| ELN Prognostic Group | |||||||
| Favorable | 18 (18%) | ||||||
| Intermediate | 17 (17%) | 4.078 | 0.494, 33.642 | 0.0697 | |||
| Adverse | 64 (64%) | ||||||
| NA | 1 (1%) | ||||||
| RAS Pathway Mutations | 14 (14%) | 6.417 | 1.813, 22.708 | 0.0039 | 2.266 | 0.201, 25.522 | 0.5080 |
| TP53 | 10 (10%) | 1.481 | 0.282, 7.766 | 0.6424 | |||
| IDH1/IDH2 | 27 (27%) | NE | NE | 0.9521 | |||
| NPM1 | 27 (27%) | 0.162 | 0.020, 1.298 | 0.0865 | 0.488 | 0.034, 6.966 | 0.5967 |
| FLT3-ITD | 18 (18%) | 0.663 | 0.136, 3.273 | 0.6119 | |||
| ASXL1 | 24 (24%) | 1.182 | 0.339, 4.122 | 0.7932 | |||
| French-American-British (FAB) Classification | |||||||
| M0/M1 | 77 (77%) | 0.131 | 0.040 0.428 |
0.0008 | |||
| M2 | 1 (1%) | ||||||
| M4 | 8 (8%) | NE | NE | 0.9745 | |||
| M5 | 13 (13%) | 18.285 | 4.701, 71.129 | <0.0001 | 33.481 | 2.657, 421.90 | 0.0066 |
| M6a | 1 (1%) | ||||||